Advertisement
Canada markets closed

  • S&P/TSX

    21,639.10
    -59.00 (-0.27%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CAD/USD

    0.7281
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    78.49
    +0.04 (+0.05%)
     

  • Bitcoin CAD

    91,316.07
    +600.70 (+0.66%)
     

  • CMC Crypto 200

    1,382.51
    -35.36 (-2.49%)
     

  • GOLD FUTURES

    2,348.40
    -0.70 (-0.03%)
     

  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • NASDAQ

    17,688.88
    +21.28 (+0.12%)
     

  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • NIKKEI 225

    38,814.56
    +94.06 (+0.24%)
     

  • CAD/EUR

    0.6801
    +0.0027 (+0.40%)
     

Stocks in play: Medicenna Therapeutics Corp.

Baystreet.ca

Announced today that the American Society of Clinical Oncology decided to reverse its decision and to withdraw Medicenna’s abstract entitled “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors,” which had been initially selected for an oral podium presentation at ASCO’s 2024 Annual Meeting. Medicenna Therapeutics Corp. shares T.MDNA are trading up $0.02 at $2.49.

Read: